Royalty Pharma (RPRX) earnings per share (EPS)

Earnings per share · fiscal 2025
$1.78

Royalty Pharma (RPRX) reported diluted earnings per share of $1.78 in fiscal 2025 (the year ended December 31, 2025). That is 23.1% higher than the $1.45 of fiscal 2024. Figures as of 17 Nov 2026, 21:06 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings per share, fiscal 2025
$1.78
Change on fiscal 2024
+23.1%
Growth, 5 years
+6.2% a year
Highest on record
$2.53fiscal 2023
Lowest on record
$0.10fiscal 2022
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Royalty Pharma earnings per share (EPS), in more detail

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 6.2% a year. Across the 6 fiscal years on record (2020–2025), the highest was $2.53 in fiscal 2023 and the lowest $0.10 in fiscal 2022.

History · 6 fiscal years

Earnings per share by fiscal year

Royalty Pharma earnings per share (EPS), year by year

Royalty Pharma (RPRX) earnings per share (EPS) by fiscal year
Fiscal yearEarnings per shareChangeYear ended
2025$1.78 23.1% up
2024$1.45 42.8% down
2023$2.53 2,430.0% up
2022$0.10 93.3% down
2021$1.49 12.9% up
2020$1.32—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

Earnings per share at health care companies of similar size

Earnings per share of Royalty Pharma and comparable companies
CompanyEarnings per shareFiscal year
IQVIA Holdings IQV$7.842025
Revolution Medicines RVMD-$5.952025
Royalty Pharma RPRX$1.782025
Biogen BIIB$8.792025
GE HealthCare Technologies GEHC$4.552025
Alcon ALC$1.982025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RPRX

Royalty Pharma, figure by figure

Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value

Royalty Pharma earnings per share (EPS): questions and answers

What is Royalty Pharma's diluted earnings per share?

Royalty Pharma (RPRX) reported diluted earnings per share of $1.78 in fiscal 2025 (the year ended December 31, 2025). That is 23.1% higher than the $1.45 of fiscal 2024.

What is the growth rate of Royalty Pharma's diluted earnings per share?

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 6.2% a year.

What are the highest and lowest diluted earnings per share figures on record for Royalty Pharma?

Across the 6 fiscal years on record (2020–2025), the highest was $2.53 in fiscal 2023 and the lowest $0.10 in fiscal 2022.

How is Royalty Pharma's diluted earnings per share calculated?

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Royalty Pharma (RPRX) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/RPRX/eps

Underlying data: the company's filings with the SEC and Yahoo Finance.